SHARE
 
Jacques Galipeau, MD close
Jacques Galipeau, MD

New Patients

Contact the Welcome Center for help choosing a new primary care doctor.

For Referring Physicians

How to refer a patient

Jacques Galipeau, MD Print Friendly Page

Faculty, University of Wisconsin School of Medicine and Public Health

Dr. Galipeau is a board certified Hematologist with an interest in benign blood disorders, including diagnostic assessment of blood count and hematology laboratory abnormalities, congenital and acquired anemia, and autoimmune blood disorders.

Specialties

Hematology

Hematology (Leukemia, Lymphoma and Multiple Myeloma)

Hematology (non cancer)

Clinics

UW Carbone Cancer Center
(608) 265-1700 | (800) 323-8942 | Map

UW School of Medicine and Public Health

Department of Medicine

Professional Certifications and Education

Board Certification Hematology
Fellowship

Hematology and Oncology, Tufts Medical Center, New England Medical Center Hospital, Boston, MA


Residency Jewish General Hospital, Montreal, Quebec, Canada
Internship Universite de Montreal, Montreal, Quebec, Canada
Medical School Universite de Montreal, Montreal, Quebec, Canada

Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.
Research

Dr. Galipeau is the Don and Marilyn Anderson Professor of Oncology within the Department of Medicine and UW Carbone Comprehensive Cancer Center at the University of Wisconsin-Madison, and the inaugural Assistant Dean for Therapeutics Discovery and Development at the UW School of Medicine and Public Health. Dr. Galipeau has initiated and developed an NIH-funded research program in the study and use of mesenchymal stromal cells as an immunotherapy of catastrophic illnesses including cancer and immune disease. He is an internationally-recognized expert in translational development of cell therapies and the sponsor of a series of FDA-sanctioned clinical trials examining the use of autologous, marrow-derived mesenchymal stromal cells for immune disorders, including Crohn's disease and graft versus host disease. He has also developed the field of fusion engineered cytokines, known as fusokines, as a novel pharmaceutical means of treating immune disorders and cancer. He is the director of the University of Wisconsin Advanced Cell Therapy Program, whose mission is to develop personalized cell therapies for immune and malignant disorders and to promote and deploy first-in-human clinical trials of cell therapy innovations to improve outcomes for children and adults.


PubMed Articles
Chinnadurai R Rajakumar A Schneider AJ Bushman WA Hematti P Galipeau J Potency Analysis of Mesenchymal Stromal Cells Using a Phospho-STAT Matrix Loop Analytical Approach. Stem Cells . 2019 Aug;37(8):1119-1125
[PubMed ID: 31108008]
Chinnadurai R Sands J Rajan D Liu X Arafat D Das R Anania FA Gibson G Kisseleva T Galipeau J Molecular Genetic and Immune Functional Responses Distinguish Bone Marrow Mesenchymal Stromal Cells from Hepatic Stellate Cells. Stem Cells . 2019 Aug;37(8):1075-1082
[PubMed ID: 31033095]
Phinney DG Galipeau J MSC COMMITTEE OF THE INTERNATIONAL SOCIETY OF CELL AND GENE THERAPY. Manufacturing mesenchymal stromal cells for clinical applications: A survey of Good Manufacturing Practices at U.S. academic centers. Cytotherapy . 2019 Jul;21(7):782-792
[PubMed ID: 31182333]
Prasanphanich AF Johnson CT Krasnopeyev A Cantara S Roach C Gumber S Chinnadurai R Galipeau J Brewster L Prologo JD Image-Guided Transarterial Directed Delivery of Human Mesenchymal Stem Cells for Targeted Gastrointestinal Therapies in a Swine Model. J Vasc Interv Radiol . 2019 Jul;30(7):1128-1134.e5
[PubMed ID: 30852052]
Martin I Galipeau J Kessler C Le Blanc K Dazzi F Challenges for mesenchymal stromal cell therapies. Sci Transl Med . 2019 Feb 20;11(480)
[PubMed ID: 30787168]
Galipeau J Weiss DJ Dominici M Response to Nature commentary "Clear up this stem-cell mess". Cytotherapy . 2019 Jan;21(1):1-2
[PubMed ID: 30551850]
Chadid T Morris A Surowiec A Robinson S Sasaki M Galipeau J Pollack BP Brewster LP Reversible secretome and signaling defects in diabetic mesenchymal stem cells from peripheral arterial disease patients. J Vasc Surg . 2018 Dec;68(6S):137S-151S.e2
[PubMed ID: 30104096]
Zhang Z Wilson NA Chinnadurai R Panzer SE Redfield RR 3rd Reese SR Galipeau J Djamali A Autologous Mesenchymal Stromal Cells Prevent Transfusion-elicited Sensitization and Upregulate Transitional and Regulatory B Cells. Transplant Direct . 2018 Sep;4(9):e387
[PubMed ID: 30234156]
Pennati A Asress S Glass JD Galipeau J Adoptive transfer of IL-10<sup>+</sup> regulatory B cells decreases myeloid-derived macrophages in the central nervous system in a transgenic amyotrophic lateral sclerosis model. Cell Mol Immunol . 2018 Jul;15(7):727-730
[PubMed ID: 29307886]
Galipeau J Sensébé L Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities. Cell Stem Cell . 2018 Jun 1;22(6):824-833
[PubMed ID: 29859173]
Nguyen DC Lewis HC Joyner C Warren V Xiao H Kissick HT Wu R Galipeau J Lee FE Extracellular vesicles from bone marrow-derived mesenchymal stromal cells support <i>ex vivo</i> survival of human antibody secreting cells. J Extracell Vesicles . 2018;7(1):1463778
[PubMed ID: 29713426]
Naskou MC Sumner SM Chocallo A Kemelmakher H Thoresen M Copland I Galipeau J Peroni JF Platelet lysate as a novel serum-free media supplement for the culture of equine bone marrow-derived mesenchymal stem cells. Stem Cell Res Ther . 2018 Mar 22;9(1):75
[PubMed ID: 29566772]
Chinnadurai R Rajan D Qayed M Arafat D Garcia M Liu Y Kugathasan S Anderson LJ Gibson G Galipeau J Potency Analysis of Mesenchymal Stromal Cells Using a Combinatorial Assay Matrix Approach. Cell Rep . 2018 Feb 27;22(9):2504-2517
[PubMed ID: 29490284]
Naskou MC Norton NA Copland IB Galipeau J Peroni JF Innate immune responses of equine monocytes cultured in equine platelet lysate. Vet Immunol Immunopathol . 2018 Jan;195:65-71
[PubMed ID: 29249319]
Rajan D Chinnadurai R O'Keefe EL Boyoglu-Barnum S Todd SO Hartert TV Galipeau J Anderson LJ Protective role of Indoleamine 2,3 dioxygenase in Respiratory Syncytial Virus associated immune response in airway epithelial cells. Virology . 2017 Dec;512:144-150
[PubMed ID: 28963880]
Lewis HC Chinnadurai R Bosinger SE Galipeau J The IDO inhibitor 1-methyl tryptophan activates the aryl hydrocarbon receptor response in mesenchymal stromal cells. Oncotarget . 2017 Nov 3;8(54):91914-91927
[PubMed ID: 29190885]
Conklin LS Hanley PJ Galipeau J Barrett J Bollard CM Intravenous mesenchymal stromal cell therapy for inflammatory bowel disease: Lessons from the acute graft versus host disease experience. Cytotherapy . 2017 Jun;19(6):655-667
[PubMed ID: 28433516]
Stenger EO Chinnadurai R Yuan S Garcia M Arafat D Gibson G Krishnamurti L Galipeau J Bone Marrow-Derived Mesenchymal Stromal Cells from Patients with Sickle Cell Disease Display Intact Functionality. Biol Blood Marrow Transplant . 2017 May;23(5):736-745
[PubMed ID: 28132869]
Galipeau J Reply: "Function of Cryopreserved Mesenchymal Stromal Cells With and Without Interferon-γ Prelicensing Is Context Dependent". Stem Cells . 2017 May;35(5):1440-1441
[PubMed ID: 27758017]
Chinnadurai R Rajan D Ng S McCullough K Arafat D Waller EK Anderson LJ Gibson G Galipeau J Immune dysfunctionality of replicative senescent mesenchymal stromal cells is corrected by IFNγ priming. Blood Adv . 2017 Apr 25;1(11):628-643
[PubMed ID: 28713871]